Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4287764 | 0.99 | GSK3B (0.38) | GSK3BSCN10ACYP1A2JAK3SLC6A3 | |
| SCHEMBL2935927 | 0.93 | GSK3B (0.45) | GSK3BSCN10AP2RX7 | |
| SCHEMBL2936761 | 0.92 | ADORA2A (0.34) | GSK3BCYP1A2JAK3SLC6A3CYP3A4 | |
| Hydrochloric Acid SCHEMBL4292984 | 0.91 | ADORA2A (0.34) | GSK3BCYP1A2JAK3SLC6A3CYP3A4 | |
| SCHEMBL2974019 | 0.81 | GSK3B (0.46) | GSK3BSCN10A | |
| Trifluoroacetic Acid SCHEMBL2929092 | 0.80 | GSK3B (0.47) | GSK3BCYP1A2CYP3A4 | |
| SCHEMBL4279898 | 0.76 | GSK3B (0.38) | GSK3B | |
| SCHEMBL13658215 | 0.76 | GSK3B (0.52) | GSK3B | |
| SCHEMBL2926618 | 0.74 | GSK3B (0.50) | GSK3B | |
| SCHEMBL2928617 | 0.74 | ADORA2A (0.36) | GSK3BCYP1A2JAK3SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | GSK3B 2707/4885SCN10A 3751/4885CYP1A2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.